Home » Stocks » ARNA

Arena Pharmaceuticals, Inc. (ARNA)

Stock Price: $80.08 USD -0.27 (-0.34%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
Market Cap 4.87B
Revenue (ttm) 319,000
Net Income (ttm) -404.73M
Shares Out 54.77M
EPS (ttm) -7.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $80.08
Previous Close $80.35
Change ($) -0.27
Change (%) -0.34%
Day's Open 81.57
Day's Range 79.96 - 81.85
Day's Volume 420,084
52-Week Range 32.95 - 90.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Schaeffers Research - 3 days ago

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry...

Other stocks mentioned: APHA, IIPR, JAZZ, SNDL, TLRY, VFF, YCBD
Zacks Investment Research - 5 days ago

Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.

Benzinga - 6 days ago

Shares of Arena Pharmaceuticals (NASDAQ:ARNA) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 19.32% year over year to ($2.10...

Business Wire - 6 days ago

SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full ye...

Benzinga - 1 week ago

On Tuesday, February 23, Arena Pharmaceuticals (NASDAQ:ARNA) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Schaeffers Research - 1 week ago

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry...

Other stocks mentioned: CGC, GWPH, HEXO, NBEV, SNDL, TLRY, YCBD
Business Wire - 1 week ago

SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new emp...

Business Wire - 1 week ago

SAN DIEGO--(BUSINESS WIRE)---- $ARNA #earnings--Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23.

Business Wire - 1 week ago

SAN DIEGO--(BUSINESS WIRE)-- #ArenaPharm--Industry veteran Garry Neil, MD named Board Chair. Nawal Ouzren, CEO of Sensorion named to Board.

Schaeffers Research - 3 weeks ago

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry...

Other stocks mentioned: GNLN, GRWG, GWPH, JAZZ, OGI, SNDL, TLRY, VFF, YCBD
Business Wire - 3 weeks ago

SAN DIEGO--(BUSINESS WIRE)---- $ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety ...

Schaeffers Research - 1 month ago

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry...

Other stocks mentioned: ACB, APHA, HUGE, IIPR, TLRY, XXII, YCBD
Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021, the Compensation Committee of its Board of Directors granted to five new employ...

Schaeffers Research - 1 month ago

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis...

Other stocks mentioned: ACB, APHA, GWPH, HEXO, VFF
Schaeffers Research - 1 month ago

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis...

Other stocks mentioned: ACB, APHA, CGC, GWPH, HEXO, OGI, SNDL, TAP
Seeking Alpha - 1 month ago

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)

PRNewsWire - 2 months ago

SAN DIEGO, Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to pr...

PRNewsWire - 2 months ago

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020, the Compensation Committee of its Board of Directors granted to f...

PRNewsWire - 2 months ago

SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a ...

Schaeffers Research - 2 months ago

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in ...

Other stocks mentioned: APHA, GWPH, OGI, SNDL, TLRY
Seeking Alpha - 3 months ago

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at 3rd Annual Evercore ISI HealthCONx Conference (Transcript)

Other stocks mentioned: EVR
Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals announces the appointment of Paul D. Streck, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer.

Schaeffers Research - 3 months ago

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in ...

Other stocks mentioned: ACB, APHA, GNLN, GWPH, IIPR, NBEV, OGI, TRPX
PRNewsWire - 3 months ago

SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on November 15, 2020, the Compensation Committee of its Board of Directors granted to 1...

Schaeffers Research - 3 months ago

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to w...

Other stocks mentioned: ACB, CGC, HEXO, HUGE, KERN, OGI, SNDL, TLRY, VFF, YCBD, ZYNE
The Motley Fool - 3 months ago

The biotech posted clinical trial data that left more to be desired.

Zacks Investment Research - 3 months ago

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.

Seeking Alpha - 3 months ago

Arena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q3 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

Shares of Arena Pharmaceuticals (NASDAQ:ARNA) decreased 19.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 15.75% over the past year...

PRNewsWire - 3 months ago

SAN DIEGO, Calif., Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended Septembe...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly select...

Insider Monkey - 4 months ago

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks...

Seeking Alpha - 4 months ago

Arena Pharmaceuticals has an impressive pipeline of compounds, and its trials are progressing well now, despite the impact of COVID-19. After its equity offering in early June at $50 per share...

PRNewsWire - 4 months ago

SAN DIEGO, Oct. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new data from the Phase 2 OASIS trial and its open-label extension for its investigative drug ca...

Seeking Alpha - 5 months ago

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at Jefferies Next Generation IBD Therapeutics Virtual Summit Call Transcript

Seeking Alpha - 5 months ago

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript)

Seeking Alpha - 5 months ago

Arena Pharmaceuticals, Inc.'s (ARNA) CEO Amit Munshi at H.C.

Seeking Alpha - 5 months ago

Arena Pharmaceuticals, Inc.'s (ARNA) CEO Amit Munshi at Wells Fargo Securities 2020 Virtual Healthcare Conference (Transcript)

Other stocks mentioned: WFC
PRNewsWire - 5 months ago

SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.

Zacks Investment Research - 5 months ago

Arena (ARNA) doses first patients in a phase II study evaluating etrasimod in patients with alopecia areata.

Seeking Alpha - 6 months ago

Exploring more about medical/pharma side of cannabis sector and thematic ETF investing.

Other stocks mentioned: ACT, CNBS, CWBHF, GRWG, GWPH, IIPR, MJ, POTX, SMG, THCX, TOKE, YOLO, ZYNE
Zacks Investment Research - 6 months ago

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

The Motley Fool - 6 months ago

But the company did provide information in its Q2 update that investors should care about.

Seeking Alpha - 6 months ago

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 6 months ago

Pharma Medical Cannabis More Robust And Resilient (Podcast)

Other stocks mentioned: ACT, CNBS, CWBHF, GRWG, GWPH, IIPR, MJ, POTX, SMG, THCX, TOKE, YOLO, ZYNE
The Motley Fool - 8 months ago

These companies are all surprising a few doubters lately.

Other stocks mentioned: CARA, FMS
PRNewsWire - 8 months ago

SAN DIEGO, June 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to its research and development leadership team. Effective June 9, 2020, Dr. Preston ...

The Motley Fool - 8 months ago

A rival's drug validates the biotech's approach.

PRNewsWire - 9 months ago

SAN DIEGO, June 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 6,325,000 shares o...

Zacks Investment Research - 9 months ago

Arena Pharmaceuticals, Inc. (ARNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

About ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 28, 2000
CEO
Amit Munshi
Employees
363
Stock Exchange
NASDAQ
Ticker Symbol
ARNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for ARNA stock is "Strong Buy." The 12-month stock price forecast is 94.73, which is an increase of 18.29% from the latest price.

Price Target
$94.73
(18.29% upside)
Analyst Consensus: Strong Buy